Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research
Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research
LINAC-based SBRT in treating early-stage NSCLC patients-single institution experience and survival data analysis
Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.PMID:38414671 | PMC:PMC10896905 | DOI:10.3389/pore.2024.1611589 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 28, 2024 Category: Pathology Authors: Árpád Kovács Krisztina Tr ási M árton Barabás Krist óf Gál Emese Csiki D ávid Sipos Judit Papp Mih ály Simon Source Type: research
LINAC-based SBRT in treating early-stage NSCLC patients-single institution experience and survival data analysis
Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.PMID:38414671 | PMC:PMC10896905 | DOI:10.3389/pore.2024.1611589 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 28, 2024 Category: Pathology Authors: Árpád Kovács Krisztina Tr ási M árton Barabás Krist óf Gál Emese Csiki D ávid Sipos Judit Papp Mih ály Simon Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research
Genetic characterization of intramuscular myxomas
Conclusion: Firstly, our data indicate a possible association between chromosomal abnormalities and GNAS pathogenic variants in intramuscular myxomas. Secondly, the presence of the rare pathogenic variants R201S, p.R201G and p.Q227E in 26% (5 out of 19) of myxomas with GNAS pathogenic variants shows that methodologies designed to detect only the common "hotspot" of p.R201C and p.R201H will give false negative results. Finally, a comparison between Ion AmpliSeq Cancer Hotspot Panel v2 and direct cycle Sanger sequencing showed that direct cycle Sanger sequencing provides a quick, reliable, and relatively cheap method to dete...
Source: Pathology Oncology Research - February 6, 2024 Category: Pathology Authors: William John Hatchett Marta Brunetti Kristin Andersen Maren Randi Tands æther Ingvild Lobmaier Marius Lund-Iversen Thomas Lien-Dahl Francesca Micci Ioannis Panagopoulos Source Type: research
Genetic characterization of intramuscular myxomas
Conclusion: Firstly, our data indicate a possible association between chromosomal abnormalities and GNAS pathogenic variants in intramuscular myxomas. Secondly, the presence of the rare pathogenic variants R201S, p.R201G and p.Q227E in 26% (5 out of 19) of myxomas with GNAS pathogenic variants shows that methodologies designed to detect only the common "hotspot" of p.R201C and p.R201H will give false negative results. Finally, a comparison between Ion AmpliSeq Cancer Hotspot Panel v2 and direct cycle Sanger sequencing showed that direct cycle Sanger sequencing provides a quick, reliable, and relatively cheap method to dete...
Source: Pathology Oncology Research - February 6, 2024 Category: Pathology Authors: William John Hatchett Marta Brunetti Kristin Andersen Maren Randi Tands æther Ingvild Lobmaier Marius Lund-Iversen Thomas Lien-Dahl Francesca Micci Ioannis Panagopoulos Source Type: research
Genetic characterization of intramuscular myxomas
Conclusion: Firstly, our data indicate a possible association between chromosomal abnormalities and GNAS pathogenic variants in intramuscular myxomas. Secondly, the presence of the rare pathogenic variants R201S, p.R201G and p.Q227E in 26% (5 out of 19) of myxomas with GNAS pathogenic variants shows that methodologies designed to detect only the common "hotspot" of p.R201C and p.R201H will give false negative results. Finally, a comparison between Ion AmpliSeq Cancer Hotspot Panel v2 and direct cycle Sanger sequencing showed that direct cycle Sanger sequencing provides a quick, reliable, and relatively cheap method to dete...
Source: Pathology Oncology Research - February 6, 2024 Category: Pathology Authors: William John Hatchett Marta Brunetti Kristin Andersen Maren Randi Tands æther Ingvild Lobmaier Marius Lund-Iversen Thomas Lien-Dahl Francesca Micci Ioannis Panagopoulos Source Type: research
Genetic characterization of intramuscular myxomas
Conclusion: Firstly, our data indicate a possible association between chromosomal abnormalities and GNAS pathogenic variants in intramuscular myxomas. Secondly, the presence of the rare pathogenic variants R201S, p.R201G and p.Q227E in 26% (5 out of 19) of myxomas with GNAS pathogenic variants shows that methodologies designed to detect only the common "hotspot" of p.R201C and p.R201H will give false negative results. Finally, a comparison between Ion AmpliSeq Cancer Hotspot Panel v2 and direct cycle Sanger sequencing showed that direct cycle Sanger sequencing provides a quick, reliable, and relatively cheap method to dete...
Source: Pathology Oncology Research - February 6, 2024 Category: Pathology Authors: William John Hatchett Marta Brunetti Kristin Andersen Maren Randi Tands æther Ingvild Lobmaier Marius Lund-Iversen Thomas Lien-Dahl Francesca Micci Ioannis Panagopoulos Source Type: research
Genetic characterization of intramuscular myxomas
Conclusion: Firstly, our data indicate a possible association between chromosomal abnormalities and GNAS pathogenic variants in intramuscular myxomas. Secondly, the presence of the rare pathogenic variants R201S, p.R201G and p.Q227E in 26% (5 out of 19) of myxomas with GNAS pathogenic variants shows that methodologies designed to detect only the common "hotspot" of p.R201C and p.R201H will give false negative results. Finally, a comparison between Ion AmpliSeq Cancer Hotspot Panel v2 and direct cycle Sanger sequencing showed that direct cycle Sanger sequencing provides a quick, reliable, and relatively cheap method to dete...
Source: Pathology Oncology Research - February 6, 2024 Category: Pathology Authors: William John Hatchett Marta Brunetti Kristin Andersen Maren Randi Tands æther Ingvild Lobmaier Marius Lund-Iversen Thomas Lien-Dahl Francesca Micci Ioannis Panagopoulos Source Type: research
